HHV Biotech
HHV Biotech is committed to tackling biofilm-related disorders, including chronic and acute infections, and antimicrobial resistance at its root cause. They use proprietary compounds with proven anti-biofilm properties and are involved in innovative research and development to combat antimicrobial resistance and biofilm-associated infections.
Industries
Nr. of Employees
small (1-50)
HHV Biotech
Leiden Bio Science Park, Mendelweg 32, 2333 CS Leiden, The Netherlands
Products
Lead anti-biofilm small-molecule clinical candidate
A clinical-stage small-molecule candidate developed to prevent or disrupt bacterial biofilms; GMP-manufactured material has been produced in quantities sufficient for IND-enabling studies and initiation of human clinical development.
Lead anti-biofilm small-molecule clinical candidate
A clinical-stage small-molecule candidate developed to prevent or disrupt bacterial biofilms; GMP-manufactured material has been produced in quantities sufficient for IND-enabling studies and initiation of human clinical development.
Services
Engagement with external partners and consortia to co-develop anti-biofilm and AMR-related programs.
Engagement with external partners and consortia to co-develop anti-biofilm and AMR-related programs.
Expertise Areas
- Anti-biofilm therapeutics
- Quorum sensing modulation
- Antimicrobial resistance (AMR) research
- Preclinical development and IND preparation
Key Technologies
- Anti-biofilm small molecules
- Quorum sensing inhibitors
- GMP drug-substance manufacturing
- Purification and downstream processing
News & Updates
HHV Biotech successfully completed GMP manufacturing of its lead drug candidate, HHV-001, which is sufficient to complete pre-clinical activities and start human clinical development.
HHV Biotech joined the BEAM alliance, a consortium of biotech companies from Europe and Israel, focused on developing innovative products to tackle antimicrobial resistance.
HHV Biotech announced the appointment of Peter Nibbering, Ph.D., as Chief Scientific Officer, bringing 30 years of experience in infection defense research.
HHV Biotech successfully completed GMP manufacturing of its lead drug candidate, HHV-001, which is sufficient to complete pre-clinical activities and start human clinical development.
HHV Biotech joined the BEAM alliance, a consortium of biotech companies from Europe and Israel, focused on developing innovative products to tackle antimicrobial resistance.
HHV Biotech announced the appointment of Peter Nibbering, Ph.D., as Chief Scientific Officer, bringing 30 years of experience in infection defense research.